Testing Data
Rabbit anti-Human Cyclin D1 Monoclonal Antibody | anti-CCND1 antibody
Anti-Cyclin D1; Rabbit Monoclonal Antibody
In 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide
WB: 1:1000- 1:2000 dilution
The antibody solution should be gently mixed before use.
Testing Data
Testing Data
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G1/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G1 phase. Hypophosphorylates RB1 in early G1 phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3; phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex; cyclin D1/CDK4/CDKN1B; required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.
NCBI and Uniprot Product Information
NCBI Description
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. [provided by RefSeq, Jul 2008]
Uniprot Description
CCND1: a member of the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb.
Protein type: Activator; Cell cycle regulation; Nuclear receptor co-regulator; Oncoprotein
Chromosomal Location of Human Ortholog: 11q13.3
Cellular Component: cyclin-dependent protein kinase holoenzyme complex; cytosol; intracellular; nucleoplasm; nucleus; transcriptional repressor complex
Molecular Function: cyclin-dependent protein kinase activity; enzyme binding; histone deacetylase binding; protein binding; protein kinase binding; transcription corepressor activity; transcription factor binding
Biological Process: G1 DNA damage checkpoint; G1/S transition of mitotic cell cycle; negative regulation of transcription from RNA polymerase II promoter; positive regulation of cell cycle; positive regulation of cyclin-dependent protein kinase activity; positive regulation of protein amino acid phosphorylation; response to DNA damage stimulus; response to drug
Disease: Myeloma, Multiple; Von Hippel-lindau Syndrome
Research Articles on CCND1
Similar Products
Product Notes
The CCND1 ccnd1 (Catalog #AAA846007) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Anti-Cyclin D1; Rabbit Monoclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's Cyclin D1 can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC); Western Blot (WB). IHC: 1:500-1:1000 dilution WB: 1:1000- 1:2000 dilution. Researchers should empirically determine the suitability of the CCND1 ccnd1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "Cyclin D1, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
